Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients.
about
Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney diseaseAsymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tablesIntradialytic hypotension and cardiac remodeling: a vicious cycle.gamma-Aminbuturic acid A receptor mitigates homocysteine-induced endothelial cell permeability.Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic reviewAsymmetric dimethylarginine, race, and mortality in hemodialysis patients.Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease.Association of asymmetric dimethylarginine and endothelial dysfunction.Effects of Oral L-Citrulline Supplementation on Lipoprotein Oxidation and Endothelial Dysfunction in Humans with Vasospastic AnginaNitric Oxide Bioavailability in Obstructive Sleep Apnea: Interplay of Asymmetric Dimethylarginine and Free Radicals.Elevated Levels of Asymmetric Dimethylarginine (ADMA) in the Pericardial Fluid of Cardiac Patients Correlate with Cardiac HypertrophyAngiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.Plasma ADMA associates with all-cause mortality in renal transplant recipients.Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.Nitric oxide synthase, ADMA, SDMA, and nitric oxide activity in the paraventricular nucleus throughout the etiology of renal wrap hypertension.Arginine, arginine analogs and nitric oxide production in chronic kidney disease.Nitric oxide deficiency in chronic kidney disease.Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease.Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.Plasma asymmetric dimethylarginine, L-arginine and left ventricular structure and function in a community-based sample.Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine.Association of plasma ADMA levels with MRI markers of vascular brain injury: Framingham offspring study.Chronobiology of arterial hypertension in hemodialysis patients: implications for home blood pressure monitoringSLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammationWhat we know about oxidative stress in patients with chronic kidney disease on dialysis--clinical effects, potential treatment, and prevention.The role of asymmetric and symmetric dimethylarginines in renal disease.Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications.Asymmetric dimethylarginine, endothelial dysfunction and renal diseaseThe sympathetic nervous system in chronic kidney disease.Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.Post-translational regulation of neuronal nitric oxide synthase: implications for sympathoexcitatory states.An Update on Intradialytic Cardiac Dysfunction.Associations of Macro- and Microvascular Endothelial Dysfunction With Subclinical Ventricular Dysfunction in End-Stage Renal Disease.Prognostic Value of the Delivery Dialysis Dose on Twice-Weekly Hemodialysis Patients.Blood pressure from childhood to adolescence in obese youths in relation to insulin resistance and asymmetric dimethylarginine.Effect of enzyme replacement therapy on serum asymmetric dimethylarginine levels, coronary flow reserve and left ventricular hypertrophy in patients with Fabry disease.Interdialytic hypertension-an update.Cardiovascular risk in chronic kidney disease: role of the sympathetic nervous system.Vitamin D and methylarginines in chronic kidney disease (CKD)Oxidative Stress in Hemodialysis Patients: A Review of the Literature.
P2860
Q24617193-1C298736-3961-4ECB-B4E6-E11286227589Q26865426-A46F963A-8CC3-4EDA-92EA-72DB51A3B734Q33359991-927669F5-AECF-4389-9B85-E02B724F5035Q33640718-34C37C5D-7C53-4DBA-92AC-466E9EED3414Q33646665-35E8DDBF-730E-4551-B757-A19E0CF6F899Q34008883-8444E61B-BCEC-4A8E-AA53-8780C58A26B5Q34201581-EF2730BA-616A-48D8-95E6-33FEE5479881Q35600450-1355F9D6-1722-4776-9BF5-EEB4743F5AC9Q35618773-E911F8BF-FC22-43AD-A88C-F7BBF4DCB4B3Q35625951-5C2FCA84-0455-4BFE-B73B-F47D1EC1B52EQ35757606-9FE02F85-D2C6-46F2-A351-D210422A207BQ35818228-357D7F54-9E60-4343-BA6A-B759AE15D56BQ35995894-69D94867-ABD8-4D62-85A2-289D6D2E71C0Q36018553-CAD15E59-4F58-41B3-B8B3-84AF3A65122FQ36042613-F981D4F0-E95B-48F6-9270-378FC6DB26BBQ36577145-3CBB87FE-81A1-49D4-B1D6-28BF55F7C327Q36967585-988805E0-385A-479A-9582-1A2AFE856BF7Q36997972-9A0FE09E-22DF-401B-BD69-7C3F6EC9E71AQ37211043-57B6704E-77FE-4995-8130-E9A2919AAF71Q37273006-79AB8FDD-A4F9-43E0-8520-6E0D68C74ACDQ37336634-B650493F-7EDE-4D71-B5F9-F3775340C346Q37359833-73874572-EFC2-4C36-AF6A-AAAFA6DA4CB6Q37366671-86C82EDD-008F-41E1-AC1C-29FA119C126DQ37477751-80F38B25-BAF0-4E23-9797-D9F22652E7DBQ37837005-48C498BE-D63F-4EB7-8328-87280DAEA849Q37858880-63A973B3-001A-44D4-9C1C-745019F3CC65Q38016491-CFE72CA1-632C-4EA0-9A00-8D71ECE92590Q38056493-3287AB00-214C-49F2-9BBD-488D49FA8274Q38112066-3946AC25-F49A-4114-9DB4-DD5859DC0C42Q38258133-853B2274-8208-4A23-BA58-AA952E25E415Q38790904-46EEAC46-5CB3-4A26-97BE-5ADBE9CAD6F2Q38807482-69D457F0-BC26-4BD3-B6D4-EB54123878EBQ38828821-B73123D4-4B46-40BD-A18F-58AA07F86DC8Q38973939-AD17234A-57F3-45D4-A797-F9C12C153D9CQ40732447-03072C33-3123-4B93-8F46-2FEAD32F65C4Q41364439-F03380C8-9471-4E60-BEE5-318B801DEBFCQ41810713-2399C88F-D49B-4652-8149-EE1EBB19E451Q41838379-862A53DC-A4D2-49A1-A815-8AD61A136D0EQ42370194-458051D5-A16A-44E4-BAA8-1B6309269737Q43375953-4C69FEE6-0A79-43B8-818D-88FB6444D937
P2860
Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Left ventricular hypertrophy, ...... DMA) in hemodialysis patients.
@en
Left ventricular hypertrophy, ...... DMA) in hemodialysis patients.
@nl
type
label
Left ventricular hypertrophy, ...... DMA) in hemodialysis patients.
@en
Left ventricular hypertrophy, ...... DMA) in hemodialysis patients.
@nl
prefLabel
Left ventricular hypertrophy, ...... DMA) in hemodialysis patients.
@en
Left ventricular hypertrophy, ...... DMA) in hemodialysis patients.
@nl
P2093
P1433
P1476
Left ventricular hypertrophy, ...... ADMA) in hemodialysis patients
@en
P2093
Alessandro Cataliotti
CREED Investigators
Francesca Mallamaci
Francesco A Benedetto
Giovanni Tripepi
Ignazio Bellanuova
Rainer Böger
Renke Maas
P304
P356
10.1046/J.1523-1755.2002.00437.X
P407
P577
2002-07-01T00:00:00Z
P5875
P6179
1015003692